HC Wainwright Reiterates Buy Rating for Aura Biosciences (NASDAQ:AURA)

Aura Biosciences (NASDAQ:AURA)‘s stock had its “buy” rating reaffirmed by equities research analysts at HC Wainwright in a research note issued on Monday,Benzinga reports. They currently have a $22.00 price objective on the stock. HC Wainwright’s price target indicates a potential upside of 194.12% from the company’s previous close.

Separately, Lifesci Capital upgraded shares of Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Stock Performance

NASDAQ AURA opened at $7.48 on Monday. The stock has a market capitalization of $373.63 million, a P/E ratio of -4.32 and a beta of 0.30. Aura Biosciences has a 1 year low of $6.63 and a 1 year high of $12.38. The business’s fifty day moving average is $7.66 and its two-hundred day moving average is $8.67.

Insider Activity

In related news, insider Los Pinos Elisabet De sold 15,955 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the transaction, the insider now directly owns 304,692 shares in the company, valued at $2,336,987.64. This represents a 4.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold 23,045 shares of company stock valued at $177,242 over the last three months. 5.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Aura Biosciences

Several hedge funds have recently bought and sold shares of AURA. Barclays PLC grew its position in Aura Biosciences by 256.5% in the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock valued at $544,000 after purchasing an additional 43,897 shares in the last quarter. State Street Corp grew its position in Aura Biosciences by 3.7% in the third quarter. State Street Corp now owns 754,803 shares of the company’s stock valued at $6,725,000 after purchasing an additional 26,841 shares in the last quarter. Geode Capital Management LLC grew its position in Aura Biosciences by 4.1% in the third quarter. Geode Capital Management LLC now owns 1,008,827 shares of the company’s stock valued at $8,990,000 after purchasing an additional 39,379 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Aura Biosciences in the 3rd quarter valued at about $1,037,000. Finally, Franklin Resources Inc. grew its position in shares of Aura Biosciences by 14.8% in the 3rd quarter. Franklin Resources Inc. now owns 1,668,960 shares of the company’s stock valued at $15,571,000 after acquiring an additional 215,597 shares during the period. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.